ADVB News & Events

Advanced Biomed announced a reverse stock split of the Company's issued and outstanding common stock at a ratio of 1 for 20 shares, which will take effect at the open of The Nasdaq Stock Market on February 20, 2026. In accordance with Section 78.320.2 of the Nevada Revised Statutes, on January 12, 2026, the holders of a majority of the outstanding voting power of the Company approved by written consent a reverse stock split of the Company's issued and outstanding shares of common stock, at a ratio of not less than 1 for 2 and not more than 1 for 100 shares, with the final ratio and timing of implementation to be determined by the board in its sole discretion, and authorized the board to effect such reverse stock split at any time thereafter. On January 30, 2026, the board approved implementation of the reverse stock split at a ratio of 1 for 20 shares. The objective of the reverse split is to enable the Company to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to evidence a minimum bid price of $1.00 per share. Upon the open of trading on February 20, 2026, the Company's common stock will begin trading on a reverse split-adjusted basis, under the same symbol "ADVB" but under a new CUSIP number, 00752P203.

Advanced Biomed announced the Company has entered into a clinical research collaboration agreement with Chi-Mei Medical Center to initiate a 120-case feasibility study designed to evaluate the predictive accuracy of the Company's A+PerfusC, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro. The feasibility study is a non-interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi-Mei Medical Center, with interim comparative data expected in May-June 2026 and full study completion targeted by year-end 2026.

Advanced Biomed entered into an agreement with an unrelated third party, Wei Ha Hui, pursuant to which the Company agreed to sell 100% of the issued and outstanding shares of Advanced Biomed Limited, a Hong Kong company and a wholly owned subsidiary of the Company, for an aggregate purchase price of $23,000 based on a valuation report commissioned by the Company, subject to the terms and conditions set forth in the Agreement. All intellectual property owned by the Hong Kong subsidiary, including intellectual property owned by Shanghai Sglcell Biotech, a wholly owned subsidiary of the Hong Kong subsidiary, was transferred to the Buyer at the closing of this transaction on December 23.